Author:
Young O.E.,Renshaw L.,Macaskill E.J.,White S.,Faratian D.,Thomas J.St.J.,Dixon J.M.
Reference11 articles.
1. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer;Jordan;Steroids,2007
2. A potent specific pure antiestrogen with clinical potential;Wakeling;Cancer Res,1991
3. ICI 182,780 (Faslodex): development of a novel, ‘pure’ antiestrogen;Howell;Cancer,2000
4. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer;Robertson;Cancer Res,2001
5. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment;Howell;J Clin Oncol,2002
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献